Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?
Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.
How this was made
The 30-second read
Why it matters
CRL’s guidance reduction and net loss are the direct fundamentals that can drive near-term repricing, while the acquisition narrative and valuation-model disagreement add uncertainty about whether the market is over- or under-reacting.
Market read
Traders should focus on how the guidance cut changes 2026 earnings expectations and whether the market’s recent momentum already discounted the reset.
What to watch
The text mentions a Cambodian primate supplier acquisition and potential regulatory/ethical risk, but provides no quantified impact on 2026 guidance, leaving uncertainty around how much of the guidance cut is structural versus temporary.
Background
The piece frames CRL’s strong 90-day and 1-year returns against a new earnings outlook reset, citing a guidance cut and a quarterly net loss with divestiture-related charges.
Ticker impact
Charles River cut 2026 GAAP EPS guidance and reported a quarterly net loss, alongside divestiture-related charges and slightly lower revenue.
Near-term volatility likely as investors reprice the 2026 earnings outlook versus the recent rebound.
The article’s newest concrete facts are the guidance cut and quarterly net loss, which directly affect forward earnings and valuation narratives.
Market effects
CRO and preclinical services peers may see read-across on demand and margin durability if investors generalize the guidance reset.
No specific regional catalyst described beyond the US-listed name’s earnings outlook.
Primarily company-specific; any global impact would be through CRO demand and primate-supply constraints, but details are limited.
Counterpoint
The article highlights a large rebound and a “fair value” narrative, suggesting some investors may already be pricing the guidance reset and focusing on longer-term cash flow power.
Key entities
- companyCharles River Laboratories International
CRL cut 2026 GAAP earnings guidance and reported a quarterly net loss, with divestiture-related charges and slightly lower revenue.
- companyK.F. (Cambodia) Ltd.
CRL signed an agreement to acquire assets of a non-human primate breeding and supply company, cited as a supply-chain bottleneck driver.
